Professor Kennedy is a Professor in Neurology and Paediatrics, Consultant and Clinical Lead in Paediatric Neurology. He has over 20 years' experience in general paediatric neurology, with a special interest in neuro-oncology.
He is a member of the UK Children's Cancer and Leukaemia CNS subgroup and European (SIOPe) Brain Tumour committees.
This funding supports the quality of survival aspects of the European clinical trial entitled SIOP-PNET5-MB. This trial is for children with medulloblastoma tumours that have been defined in the clinic as "standard risk". The purpose of the trial is to assess whether treatment can be reduced so that these children experience less long term side effects, but still benefit from the anti-tumour activity of the protocol.
A key part if this trial is to make sure that the decreased treatment has a real benefit to children in terms of their long term quality of life. Professor Kennedy and his team have spent many years developing ways to measure quality of life aspects from the perspective of the child, as well as their parents. This work is now being put in place as a formal part of the PNET5 trial.
The team will be helping clinicians across Europe to administer special questionnaires so they can assess things like memory, mobility and behaviour as well as how the child, and their parents perceive their ongoing health and wellbeing. This is a real step towards halving the harm of children going through treatment.
Research is the only way we will discover kinder, more effective treatments and, ultimately, stamp out brain tumours – for good! However, brain tumours are complex and research in to them takes a great deal of time and money.
Across the UK, over 100,000 families are facing the overwhelming diagnosis of a brain tumour and it is only through the generosity of people like you can we continue to help them.
But, by setting up a regular gift – as little as £2 per month - you can ensure that families no longer face this destructive disease.